explore -WSS

explore

author：hotspot 2025-09-27 23:00:54 - browse：679

Vertex Pharmaceuticals - sunset — Bill Sikes/AP

Vertex Pharmaceuticals has spent decades trying to develop molecules that reduce pain safely and potently, searching for success in a field its own executives have dubbed a graveyard for drug discovery. Detailed data published Wednesday lent support to that quest, with a pair of company-sponsored clinical trials showing an experimental non-opioid therapy reduced pain after surgery.

The drug, VX-548, blocks signals from pain-sensitive neurons before those electrical messages reach the brain. And in a pair of randomized trials, patients given a high dose of the oral medication after bunion surgery or abdominoplasty (a tummy tuck) reported less pain than those given a placebo. Those taking lower doses of the treatment showed no improvement compared to the placebo group, however.

While the pain reduction measured by these Phase 2 trials was statistically significant, it’s unclear how meaningful the drug’s benefits were to patients, with a commentary accompanying the study describing the treatment effect as “small.” But the study authors noted that participants on a high dose of VX-548 were less likely to prematurely stop their treatment because it wasn’t working than those on placebo or participants given a combination of two common painkillers, acetaminophen and hydrocodone.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： The surgeon had a dilemma only a Nazi medical text could resolve

explore

WSS

Physicians aren't 'burning out.' They're suffering from moral injury

How to ethically and practically extend health care to all

Why doctors need education on FDA device approval process

FDA clears AI tool for detecting skin cancer

Prior authorization will have to move faster under new Biden rule

FDA scientists endorse Pfizer/BioNTech Covid

knowledge

explore

explore

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

The cancer drug shortage isn’t new — and neither are the solutions

Medicare Advantage today, explained in one chart

Medical leaders decry Supreme Court decision on affirmative action

Physicians aren't 'burning out.' They're suffering from moral injury

The cancer drug shortage isn’t new — and neither are the solutions

Dewpoint Therapeutics lays off staff after losing partnerships

As demand for Covid shots wanes, Moderna seeks its next success

Alnylam reports growth in sales of rare disease treatments

Wikipedia

NIH director takes cautious approach to Biden drug pricing priority

EU regulator recommends expanding Mounjaro approval to obesity

Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

eGenesis tests gene

FDA clears AI tool for detecting skin cancer

FDA approves Sage Therapeutics’ rapid

Wikipedia

explore

knowledge

hotspot